Briefing · · 19 min read
Pre-Launch Market Research in Pharma and Life Sciences: How AI Synthetic Audiences Compress the Launch Window
In 2026, roughly 60% of new drug launches will miss their first-year sales forecasts. That number has not meaningfully improved in two decades, despite the industry accumulating more research, more data, more launch playbooks, and more sophisticated analytics than at any point in its history.
The structural pattern behind two decades of launch underperformance
A recent retrospective of 340 drug launches between 2008 and 2025 found that clinical differentiation alone lifts overperformance rates from 44% to 49% — meaningful but, on its own, not decisive.
Industry studies attribute the failure pattern to three structural causes that recur across therapy areas: limited market access (cited in roughly 57% of failed launches), inadequate understanding of market and customer needs (47%), and poor product differentiation (41%). These are not new problems. They are persistent ones. And every one of them traces back, at some point in the 18-month pre-launch window, to a research gap that nobody had time, budget, or method to close.
This is the piece for the brand directors, launch leads, heads of insights, market access strategists, and medical affairs leaders who are sitting six to eighteen months out from a launch right now and watching the calendar move faster than the research can. It is also for the chief commercial officers and chief marketing officers who have been told for years that "more research" is the answer to launch underperformance — and have noticed that more research alone does not seem to be improving the numbers.
The argument here is straightforward: pre-launch market research in pharma is not failing because researchers are not excellent. It is failing because the operating tempo of a 2026 launch has decoupled from the tempo of the research methods that were built for a different decade. AI-powered synthetic audiences, deployed inside a Decision Intelligence layer, are the bridge — and they are reshaping what pre-launch readiness actually means.
The 18-month pre-launch window has compressed faster than the research methods
For most of pharma's modern history, the pre-launch playbook ran on roughly an eighteen-month clock from late Phase 3 readouts to commercial launch. Inside that window, the brand team was expected to validate positioning, refine segmentation, finalize messaging, build the access strategy, prepare the field, design the patient services architecture, align the medical affairs narrative, and pressure-test the launch sequence against a realistic competitive scenario.
That clock no longer exists. Three structural changes have compressed it.
Indication windows are narrower and competitors are faster. Specialty therapies now represent roughly 75% of the active pipeline. In specialty markets — particularly oncology, rare disease, and increasingly immunology — the time between a positive Phase 3 readout and a competitor's announcement of a follow-on indication has dropped sharply. Brand teams that used to have eighteen months now have eight to twelve.
Exclusivity erosion is reshaping launch economics. More than 190 products are forecast to lose exclusivity between 2022 and 2030, putting an estimated $300 billion in sales at risk before 2028. The financial logic of every launch is now compressed: the brand must capture share faster, hold it longer, and defend it harder, because the post-exclusivity recovery window is shorter than it used to be.
Stakeholder fragmentation has multiplied the decisions a launch has to get right. A modern launch has to land simultaneously with HCPs in academic centers and community settings, payers at the national PBM level and the regional plan level, P&T committees and IDN access pathways, patients and caregivers in increasingly digital pathways, and an internal field force that needs to be ready on day one. Each of those audiences has its own research requirement, its own messaging architecture, and its own success criteria.
The math of traditional pre-launch research no longer closes. A typical primary HCP segmentation refresh takes twelve to sixteen weeks end-to-end. A specialist physician quant in a competitive class can run between $150K and $400K, with rare-disease KOL work easily clearing $1,500 per completed interview. A pre-launch patient research wave, particularly in protected categories, can run six months from kickoff to readout once IRB, recruitment, and DTC compliance friction are accounted for. Stacked across an eight-to-twelve-month window with simultaneous payer, patient, HCP, and field workstreams, the calendar simply cannot absorb the volume of decisions the brand has to make.
This is what every brand team senses but few say out loud: the research budget is large, the research is excellent, and the research arrives too late to influence the decisions it was supposed to inform.
Where pre-launch market research actually breaks down
The launch failure data points to specific decision classes where the research-to-decision gap consistently produces commercial damage. Five recur often enough that they should be treated as the structural breakpoints of the pre-launch window.
1. HCP perception is built on a snapshot, not a trajectory
Most pre-launch HCP research happens as a quantitative wave around twelve to nine months before launch, with possibly one qualitative round of advisory boards, then a tracking study at launch. The decisions that need HCP input — message refinement, sales aid design, congress strategy, rep training content, peer-to-peer narrative — happen in roughly twenty different moments inside that window. Most of them are made without going back to the audience.
The result is messaging that was right twelve months ago, lands flat at launch because the competitive context, the published evidence, or the indication framing has moved.
2. Payer research is asymmetric to commercial timing
Payer research is the single most leveraged input into launch success — more than half of failed launches name market access as a primary cause. Yet payer research is also the most slow-moving and expensive part of the pre-launch suite. P&T committee dynamics, formulary modeling, prior authorization design, and HEOR value-story development all sit on top of small, hard-to-recruit panels that cannot be queried iteratively at the pace decisions actually require.
When the brand team makes a packaging decision, a price-corridor decision, or a contracting decision under time pressure, they almost never have the option to "go back to payers" the way they would go back to HCPs.
3. Patient journey research goes stale faster than anyone wants to admit
The patient journey work that informed the launch strategy was usually done in Phase 2 or early Phase 3 — sometimes two or three years before launch. In that interval, treatment standards shift, digital health adoption changes the diagnostic pathway, advocacy organizations evolve, and the lived experience of patients in the category meaningfully changes. The journey deck in the brand plan often describes a patient who no longer exists.
4. Differentiation breaks down at the moment of choice
A 2025 customer experience study of 690 U.S. board-certified specialists used derived importance modeling to compare what physicians say drives prescribing decisions against what actually drives them. The gap was large. Brands that built their pre-launch differentiation strategy on stated preferences ended up with messaging that did not survive the moment of clinical choice.
This is the failure mode that is hardest to detect inside traditional research, because it requires testing the actual decision moment against a calibrated audience — not asking the audience what it would do in theory.
5. Launch readiness is rarely rehearsed end-to-end
By the time the brand team has finished its segmentation, messaging, access strategy, patient services design, field training, and congress plan, almost nobody inside the organization has the time, budget, or method to simulate the full launch — to walk a realistic month one, month three, month six scenario across all stakeholders simultaneously and see where the architecture breaks. Launches go live into the real world without having been rehearsed end-to-end. The failures that emerge in the first ninety days are usually the ones that would have been caught in a serious rehearsal.
These five breakdowns are where 60% of launches accumulate the gaps that turn into commercial underperformance. They are also exactly the breakdowns that pre-launch synthetic audiences are positioned to close.
What compressing the launch window actually means
The job of pre-launch Decision Intelligence is not to replace primary research. It is to fill the gaps between research waves with calibrated, queryable, audit-ready audiences that allow the brand team to make the daily decisions a launch generates without waiting for a study they cannot afford to run.
Five pre-launch use cases consistently produce asymmetric value when synthetic audiences are deployed correctly. The goal is not to do less research. It is to make every research dollar already spent compound across every decision the brand team has to make between now and launch.
1. Message and concept rehearsal at the speed of the agency cycle
A brand team typically generates two to four message variants per workstream per cycle. Across the eight to twelve weeks before a critical creative decision, that is twenty to forty variants the team should be testing. Traditional research can handle three or four. A pre-launch synthetic audience built from the brand's own segmentation can test all of them, surface the objection patterns and comprehension gaps, and narrow the slate before the next agency review. The real-respondent validation still happens. It happens on a sharper shortlist with a clearer hypothesis.
2. Payer scenario simulation without the panel bottleneck
Pre-launch payer research will always have a real-respondent floor — the senior payer voice cannot be replaced. But the iterative testing of access scenarios, contracting structures, value-story variants, and HEOR framing can be modeled against synthetic payer audiences grounded in the actual payer research the brand has already commissioned. Decisions that would otherwise wait six weeks for the next payer wave can be made in days, with the formal payer research reserved for the high-stakes validation moments.
3. Patient journey re-grounding
Synthetic patient personas built from prior journey research, condition-specific qualitative, advocacy partnerships, and claims patterns can be re-grounded as the launch window unfolds — surfacing the diagnostic friction, treatment-initiation barriers, and adherence dynamics the original journey work missed or has since drifted past. None of this replaces real patient input in the moments that matter. It does mean the patient services team is no longer designing programs against a journey deck from 2023.
4. Field rehearsal and rep enablement
The rep conversation is the most leveraged touchpoint in commercial launch — and the least rehearsed. Synthetic HCP personas grounded in the actual scientific platform allow reps and MSLs to rehearse difficult conversations weeks before launch: the formulary objection, the off-label question, the comparative-efficacy challenge, the safety dialogue. By the time the field force is in the room with real physicians, they have had structured deliberate practice against calibrated personas, not just a training deck.
5. End-to-end launch readiness simulation
The highest-stakes pre-launch application — and the one that nothing else in the existing market research stack can do well — is rehearsing the launch architecture as an integrated system. What happens in month one across HCP perception, payer access, patient initiation, field execution, and competitive response? Where does the architecture break? Which assumptions, in retrospect, will look obvious? A pre-launch Decision Intelligence layer makes that rehearsal possible before the launch is in market, not as a post-mortem after.
The teams that compound this most effectively run the simulation three times in the final six months: once to find the structural breaks, once to validate the fixes, once to stress-test under realistic competitive scenarios.
The pre-launch decision intelligence workflow
The brand teams getting the most leverage from pre-launch synthetic audiences follow a consistent operating pattern. It looks less like running studies and more like running an operating layer.
The grounding phase (months 12–18 before launch). Aggregate every relevant research asset the brand owns — segmentation, U&A, journey research, qualitative transcripts, advisory board outputs, claims data, sales intelligence, congress and KOL inputs. The audience modeling layer is only as good as what it is grounded in, and the brands that win the launch are the ones that bring serious grounding to the platform from day one.
The calibration phase (months 9–12). Benchmark the synthetic audiences against a known real-respondent reference panel on a representative sample of pre-launch decisions. Document the variance. Identify the decision classes where calibration is strong and the ones where it requires more grounding. This is also where the medical-legal team, the compliance team, and the head of insights agree on what synthetic outputs can and cannot be used for inside the launch.
The active workflow phase (months 6–9). Synthetic audiences become a daily decision layer. Message variants are tested in hours. Payer scenarios are modeled in afternoons. Patient services concepts are pressure-tested before they reach pilot. Real-respondent research continues — but now reserved for the high-stakes validation moments that justify its cost and timeline.
The rehearsal phase (months 3–6). Launch readiness simulations are run end-to-end. Field rehearsal modules go live. Edge-case decisions — the safety dialogue, the off-label question, the competitive-response scenario — are stress-tested with the synthetic audience layer.
The launch and learning phase (months 0–3). The platform is now in production. Every real-world signal — first prescriptions, first denials, first adherence drops, first competitive moves — feeds back into the audience modeling layer, sharpening the calibration for the next decision and, ultimately, for the next launch the organization runs.
This is what we mean when we describe pre-launch Decision Intelligence as compressing the window. The window is not actually shorter. The number of decisions the brand team can rehearse, calibrate, and de-risk inside the same window is dramatically larger.
What this does not replace
This is the section that should be in every honest piece on AI in pre-launch research and almost never is.
Pre-launch synthetic audiences do not replace advisory boards. They do not replace the senior payer voice. They do not replace the real KOL conversation. They do not replace the lived-experience patient voice when patient organizations and advocacy groups are part of the launch architecture. They do not replace the regulatory conversation with FDA on AI-related questions in promotional and medical materials.
What they replace — and they should replace — is the long tail of decisions that historically got no rigor at all because the budget and the timeline could not stretch to cover them. The brand director's quiet 9pm decision about which of three message variants to send to the agency. The market access lead's Friday afternoon judgment call on a contracting scenario nobody had time to formally research. The patient services team's best-guess on a copay program structure. The field training lead's choice of which three rep objections to script first.
These decisions have always been made. They have just been made without data. Pre-launch Decision Intelligence is the layer that finally allows them to be made with rigor.
Why this compounds across the portfolio
A single launch that uses pre-launch synthetic audiences well captures meaningful value: faster decision cycles, sharper messaging, fewer late surprises, a more rehearsed field force, a more credible launch readiness story to executive leadership.
The second launch captures something more interesting: the audience modeling layer is now richer, the calibration is tighter, and the workflow patterns are documented. Every research dollar the organization spent on the first launch is still producing decisions for the second.
The third launch is where the architecture stops being a tool and starts being infrastructure. The brand team starts a new launch with an inherited audience modeling layer, an inherited calibration history, an inherited library of decision artifacts, and an inherited governance framework that is already approved by medical-legal and compliance. The organizations that have done this for three launches in a row are operating on a different cost curve, a different speed curve, and a different launch success curve than the ones still running each launch from a blank page.
A recent industry retrospective made this point directly: organizations that achieve repeat launch performance share a common pattern of sustained organizational commitment — barrier removal, support architecture, access infrastructure, and institutional follow-through that compounds across launches. Decision Intelligence is the substrate that makes that compounding possible at the research and decision-rehearsal layer. Without it, every launch starts at zero. With it, every launch inherits.
Closing: the launches that compound, and the ones that restart at zero
The single most important pattern in modern pharma launches is the one separating the organizations whose third launch is dramatically better than their first from the ones whose third launch looks identical to the one before it. The ones that compound have built systems. The ones that restart at zero have run projects.
Pre-launch synthetic audiences, deployed inside a serious Decision Intelligence layer, are how the next decade of launches will compound. Every research asset becomes infrastructure. Every calibration round sharpens the next one. Every rehearsal produces a more decision-grade output. Every launch inherits the operating layer the prior one paid for.
The 60% launch failure rate has not improved in twenty years. It is not going to improve through more reports, more decks, more studies, or more late-stage tactical adjustments. It is going to improve through pre-launch architecture that turns the eighteen-month window into a continuous decision workflow rather than a sequence of expensive, slow, disconnected research waves.
That is the architecture we are building at Acumen, and that is why pre-launch is the use case where life sciences buyers see the fastest return.
About Acumen. Acumen is the Decision Intelligence platform for the human layer of enterprise, and the AI-native realization of the Customer Experience Operating System. We help pharma, biotech, healthcare, and life sciences organizations model how real audiences — HCPs, patients, payers, caregivers, and commercial stakeholders — will respond to brand, message, and experience decisions, before those decisions are made. Built by G & Co., Acumen is deployed inside enterprise life sciences organizations including pre-launch brand teams, medical affairs functions, and global commercial operations.
For pre-launch deployment briefings, calibration methodology, design partner conversations, or category direction discussions, contact the Acumen team.